Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.
Location: United States
Total raised: $234.5M
Investors 3
| Date | Name | Website |
| 29.12.2024 | ARCH Ventu... | archventur... |
| 27.12.2024 | AN Venture... | an.vc |
| 10.07.2026 | Sofinnova ... | sofinnova.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 09.06.2026 | Series B | $99.5M | Fidelity M... |
| 14.10.2024 | - | $135M | - |
Mentions in press and media 6
| Date | Title | Description |
| 09.06.2026 | City Therapeutics Raises $99.5M in Series B Funding | City Therapeutics, Inc., a Cambridge, MA-based biopharmaceutical company developing RNA interference (RNAi)-based medicines, raised $99.5M in Series B funding. The round was led by Viking Global Investors and Sofinnova Investments with part... |
| 09.06.2026 | City Therapeutics Secures $99.5M Series B for RNAi | Next-gen RNA interference (RNAi) innovator City Therapeutics has announced a huge Series B round of $99.5 million to push forward its burgeoning pipeline and platform. This was less than two years from the US company’s debut Series A of $13... |
| 09.06.2026 | City Therapeutics Raises $99.5 Million Series B to Advance Next-Generation RNAi Therapies | City Therapeutics announced the completion of a $99.5 million Series B financing to support the advancement of its next-generation RNA interference (RNAi) platform and pipeline of therapies targeting serious diseases. The financing attracte... |
| 14.10.2024 | City Therapeutics Launches with $135 Million in Funding Only paid subscribers can comment on this post | City Therapeutics is a biotechnology company focused on addressing current challenges in RNA-based treatments, such as off-target effects, stability issues, and delivery mechanisms, to unlock new levels of precision and therapeutic potentia... |
| 08.10.2024 | City Therapeutics Raises $135M in Series A Financing | City Therapeutics, a Cambridge, MA-based biopharmaceutical company which specializes in RNA interference (RNAi)-based medicine, raised $135M in Series A funding. The round was led by ARCH Venture Partners with participation from Fidelity Ma... |
| - | City Therapeutics | “City Therapeutics” |